Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%.

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Senate Majority Leader Nicole Cannizzaro and Assembly Speaker Steve Yeager made the comments during a meeting of the Interim Finance Committee after Senate Minority Leader Robin Titus suggested there ...

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Plexi Images / GHI / UCG / Universal Images Group via Getty Images Moderna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S ...

As for 2024, Moderna says it reeled in sales between $3 billion and $3.1 billion, a result that came in at the low end of the company’s previous guidance range of $3 billion to $3.5 billion.

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...